Candy Bermingham, Ph.D.

Vice President, Clinical Science

Dr. Bermingham has served as our Vice President of Clinical Science since December 2020. She has 20 years’ experience within the biotech and pharmaceutical industry, leading target discovery research and early/ late-stage clinical development programs. Dr. Bermingham has been responsible for numerous Investigational New Drug (IND) submissions for immuno-oncology and oncology targeted therapies, and is the holder of nine patents. At Tallac, she leads Clinical Development and Operations. She joins Tallac from Aduro Biotech, where she served as Head of Clinical Science and was the clinical development leader for the collaboration with Novartis. Prior to Aduro, Dr. Bermingham held multiple clinical development positions within the field of oncology, serving as Senior Director, Clinical Science at Exelixis and Director, Study Clinician at Pfizer. Early in her career, she led the target validation efforts for oncology target discovery research at Celera Genomics. Dr. Bermingham holds a Ph.D. in Biochemistry and Applied Molecular Biology from the University of Manchester, UK and completed her postdoctoral training in hematopoietic stem cell biology at Yale School of Medicine.